Cocrystal Pharma Stock Market Value
| COCP Stock | USD 0.96 0.03 3.23% |
| Symbol | Cocrystal |
Can Pharmaceuticals industry sustain growth momentum? Does Cocrystal have expansion opportunities? Factors like these will boost the valuation of Cocrystal Pharma. Projected growth potential of Cocrystal fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Cocrystal Pharma demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (0.93) | Revenue Per Share | Quarterly Revenue Growth 0.269 | Return On Assets | Return On Equity |
Understanding Cocrystal Pharma requires distinguishing between market price and book value, where the latter reflects Cocrystal's accounting equity. The concept of intrinsic value - what Cocrystal Pharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Cocrystal Pharma's price substantially above or below its fundamental value.
It's important to distinguish between Cocrystal Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cocrystal Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Cocrystal Pharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cocrystal Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cocrystal Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cocrystal Pharma.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Cocrystal Pharma on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Cocrystal Pharma or generate 0.0% return on investment in Cocrystal Pharma over 90 days. Cocrystal Pharma is related to or competes with Evogene, Imunon, Sensei Biotherapeutics, Marker Therapeutics, Traws Pharma, BioRestorative Therapies, and Dogwood Therapeutics. Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treat... More
Cocrystal Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cocrystal Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cocrystal Pharma upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 20.52 | |||
| Value At Risk | (5.41) | |||
| Potential Upside | 6.67 |
Cocrystal Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cocrystal Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cocrystal Pharma's standard deviation. In reality, there are many statistical measures that can use Cocrystal Pharma historical prices to predict the future Cocrystal Pharma's volatility.| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.24) | |||
| Total Risk Alpha | (0.37) | |||
| Treynor Ratio | (0.04) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cocrystal Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cocrystal Pharma February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.03) | |||
| Mean Deviation | 2.59 | |||
| Coefficient Of Variation | (4,568) | |||
| Standard Deviation | 3.75 | |||
| Variance | 14.03 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.24) | |||
| Total Risk Alpha | (0.37) | |||
| Treynor Ratio | (0.04) | |||
| Maximum Drawdown | 20.52 | |||
| Value At Risk | (5.41) | |||
| Potential Upside | 6.67 | |||
| Skewness | 0.8034 | |||
| Kurtosis | 2.5 |
Cocrystal Pharma Backtested Returns
Cocrystal Pharma secures Sharpe Ratio (or Efficiency) of close to zero, which signifies that the company had a close to zero % return per unit of standard deviation over the last 3 months. Cocrystal Pharma exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Cocrystal Pharma's risk adjusted performance of (0.01), and Mean Deviation of 2.59 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 2.51, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cocrystal Pharma will likely underperform. At this point, Cocrystal Pharma has a negative expected return of -0.0327%. Please make sure to confirm Cocrystal Pharma's total risk alpha, as well as the relationship between the skewness and day median price , to decide if Cocrystal Pharma performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.09 |
Virtually no predictability
Cocrystal Pharma has virtually no predictability. Overlapping area represents the amount of predictability between Cocrystal Pharma time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cocrystal Pharma price movement. The serial correlation of 0.09 indicates that less than 9.0% of current Cocrystal Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.09 | |
| Spearman Rank Test | 0.13 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Pair Trading with Cocrystal Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cocrystal Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cocrystal Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Cocrystal Stock
The ability to find closely correlated positions to Cocrystal Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cocrystal Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cocrystal Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cocrystal Pharma to buy it.
The correlation of Cocrystal Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cocrystal Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cocrystal Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cocrystal Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Cocrystal Stock Analysis
When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.